Pharmacological treatment of tardive dyskinesia: recent developments

Expert Review of Neurotherapeutics

Volumn 17, Issue 9, 2017, Pages 871-881

  Caroff, Stanley N ^a   Campbell, E Cabrina ^a   Carroll, Benjamin ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b TEVA PHARMACEUTICALS   (Israel)

Author keywords

Antidyskinetic; antipsychotic; supplement; tardive dyskinesia; treatment

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; ALPHA TOCOPHEROL; AMANTADINE; ANTIPARKINSON AGENT; BOTULINUM TOXIN A; CALCIUM CHANNEL BLOCKING AGENT; CHOLINERGIC RECEPTOR STIMULATING AGENT; GAMMA LINOLENIC ACID; GINKGO BILOBA EXTRACT; LEVETIRACETAM; MELATONIN; NEUROLEPTIC AGENT; PIRACETAM; PROPRANOLOL; PYRIDOXINE; TETRABENAZINE; VESICULAR MONOAMINE TRANSPORTER 2; ZONISAMIDE; ADRENERGIC RECEPTOR AFFECTING AGENT; ANTICONVULSIVE AGENT; CHOLINESTERASE INHIBITOR; SLC18A2 PROTEIN, HUMAN; VESICULAR MONOAMINE TRANSPORTER;

CLINICAL EVALUATION; DISEASE SEVERITY; EVIDENCE BASED PRACTICE; GINKGO BILOBA; HERBAL MEDICINE; HUMAN; MANAGED CARE; MEDLINE; META ANALYSIS (TOPIC); MOTOR DYSFUNCTION; OPEN STUDY; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; TARDIVE DYSKINESIA; ANTAGONISTS AND INHIBITORS;

ADRENERGIC UPTAKE INHIBITORS; ANTICONVULSANTS; ANTIPSYCHOTIC AGENTS; CALCIUM CHANNEL BLOCKERS; CHOLINESTERASE INHIBITORS; GABA AGONISTS; HUMANS; TARDIVE DYSKINESIA; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 85028416896     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1080/14737175.2017.1358616     Document Type: Review

References (70)

1. Caroff SN, Campbell EC., Drug-induced extrapyramidal syndromes:implications for contemporary practice. Psychiatr Clin North Am. 2016;39:391–411.•• Clinically relevant comprehensive review of antipsychotic-induced, extrapyramidal side effects including a review of and treatment algorithm for tardive dyskinesia.
2. Cunningham-Owen DG., A guide to the extrapyramidal side-effects of antipsychotic drugs. 2nd ed. New York (NY):Cambridge University Press; 2014.•• Broad and in-depth resource textbook covering extrapyramidal side effects and syndromes associated with antipsychotic drugs. One of the best and most extensive reviews of movement disorders associated with severe mental disorders.
3. Adrianzen C, Arango-Davila C, Araujo DM, et al. Relative association of treatment-emergent adverse events with quality of life of patients with schizophrenia:post hoc analysis from a 3-year observational study. Hum Psychopharmacol. 2010;25:439–447.
4. Ascher-Svanum H, Zhu B, Faries D, et al. Tardive dyskinesia and the 3-year course of schizophrenia:results from a large, prospective, naturalistic study. J Clin Psychiatry. 2008;69(10):1580–1588.
5. Jankovic J. Tardive syndromes and other drug-induced movement disorders. Clin Neuropharmacol. 1995;18:197–214.
6. Woods SW, Morgenstern H, Saksa JR, et al. Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications:a prospective cohort study. J Clin Psychiatry. 2010;71:463–474.
7. Seigneurie AS, Sauvanaud F, Limosin F. Prevention and treatment of tardive dyskinesia caused by antipsychotic drugs. Encephale. 2016;42:248–254.
8. Bakker PR, De Groot IW, Van Os J, et al. Long-stay psychiatric patients:a prospective study revealing persistent antipsychotic-induced movement disorder. PLoS One. 2011;6:e25588.
9. Janno S, Holi M, Tuisku K, et al. Prevalence of neuroleptic-induced movement disorders in chronic schizophrenia patients. Am J Psychiatry. 2004;161:160–163.
10. O’Brien A. Comparing the risk of tardive dyskinesia in older adults with first-generation and second-generation antipsychotics:a systematic review and meta-analysis. Int J Geriatr Psychiatry. 2016;31:683–693.
11. Alexopoulos GS. Lack of complaints in schizophrenics with tardive dyskinesia. J Nerv Ment Dis. 1979;167:125–127.
12. Macpherson R, Collis R. Tardive dyskinesia. Patients’ lack of awareness of movement disorder. Br J Psychiatry. 1992;160:110–112.
13. Bhidayasiri R, Fahn S, Weiner WJ, et al. Evidence-based guideline:treatment of tardive syndromes:report of the guideline development subcommittee of the American Academy Of Neurology. Neurology. 2013;81(5):463–469.•• The most recent thorough meta-analysis of treatment studies of tardive dyskinesia.
14. Soares-Weiser K, Fernandez HH. Tardive dyskinesia. Semin Neurol. 2007;27(2):159–169.
15. Essali A, Deirawan H, Soares-Weiser K, et al. Calcium channel blockers for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2011;11:CD000206.
16. Alabed S, Latifeh Y, Mohammad HA, et al. Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2011;(4):CD000203.
17. Adelufosi AO, Abayomi O, Ojo TM. Pyridoxal 5 phosphate for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2015;(4):CD010501.
18. Zheng W, Xiang YQ, Ungvari GS, et al. Extract of Ginkgo biloba for tardive dyskinesia:meta-analysis of randomized controlled trials. Pharmacopsychiatry. 2016;49:107–111.
19. Cortese L, Caligiuri MP, Williams R, et al. Reduction in neuroleptic-induced movement disorders after a switch to quetiapine in patients with schizophrenia. J Clin Psychopharmacol. 2008;28(1):69–73.
20. Caroff SN, Davis VG, Miller DD, et al. Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia. J Clin Psychiatry. 2011;72:295–303.• Secondary analysis of one of the largest samples of patients with chronic schizophrenia and tardive dyskinesia, who were randomized to treatment with SGAs. Provides important evidence on the prognosis and course of tardive dyskinesia during continued treatment with antipsychotics.
21. O’Brien CF, Jiminez R, Hauser RA, et al. NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia:a randomized, double-blind, placebo-controlled study. Mov Disord. 2015;30:1681–1687.• Original RCT providing evidence of the efficacy of valbenazine.
22. Hauser R, Factor S, Marder S, et al. KINECT 3:a Phase 3 randomised, double-blind, placebo-controlled trial of valbenazine for tardive dyskinesia. Am J Psychiatry. 2017;174:476–484.• Original RCT providing evidence of the efficacy of valbenazine.
23. Fernandez HH, Factor SA, Hauser RA, et al. Randomized controlled trial of deutetrabenazine for tardive dyskinesia:the ARM-TD study. Neurology. 2017;88(21):2003–2010.• Original RCT providing evidence of the efficacy of deutetrabenazine.
24. Anderson KE, Stamler D, Davis MD, et al. Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD):a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Psychiatry. 2017 Jun 28. 10.1016/S2215-0366(17)30236-5.• Original RCT providing evidence of the efficacy of deutetrabenazine.
25. Caroff SN, Walker P, Campbell C, et al. Treatment of tardive dyskinesia with galantamine:a randomized controlled crossover trial. J Clin Psychiatry. 2007;68(3):410–415.
26. Pappa S, Tsouli S, Apostolou G, et al. Effects of amantadine on tardive dyskinesia:a randomized, double-blind, placebo-controlled study. Clin Neuropharmacol. 2010;33:271–275.
27. Woods SW, Saksa JR, Baker CB, et al. Effects of levetiracetam on tardive dyskinesia:a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2008;69(4):546–554.
28. Libov I, Miodownik C, Bersudsky Y, et al. Efficacy of piracetam in the treatment of tardive dyskinesia in schizophrenic patients:a randomized, double-blind placebo-controlled crossover study. J Clin Psychiatry. 2007;68(7):1031–1037.
29. 6 treatment for tardive dyskinesia:a randomized, double-blind, placebo-controlled, crossover study. J Clin Psychiatry. 2007;68(11):1648–1654.
30. Castro F, Carrizo E, Prieto De Rincon D, et al. Effectiveness of melatonin in tardive dyskinesia. Investig Clin. 2011;52(3):252–260.
31. Rajarethinam R, Dziuba J, Manji S, et al. Use of aripiprazole in tardive dyskinesia:an open label study of six cases. World J Biol Psych. 2009;10(4 Pt 2):416–419.
32. Lin CC, Bai YM, Chen JY, et al. Treatment of clozapine-associated tardive dyskinesia. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(2):599–600.
33. Lin CC, Chiu HJ, Chen JY, et al. Switching from clozapine to zotepine in patients with schizophrenia:a 12-week prospective, randomized, rater blind, and parallel study. J Clin Psychopharmacol. 2013;33:211–214.
34. Iwata Y, Irie S, Uchida H, et al. Effects of zonisamide on tardive dyskinesia:a preliminary open-label trial. J Neurol Sci. 2012;315:137–140.
35. Slotema CW, Van Harten PN, Bruggeman R, et al. Botulinum toxin in the treatment of orofacial tardive dyskinesia:a single blind study. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(2):507–509.
36. Miyaoka T, Furuya M, Yasuda H, et al. Yi-gan san for the treatment of neuroleptic-induced tardive dyskinesia:an open-label study. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(3):761–764.
37. Lee JG, Shin BS, Lee YC, et al. Clinical effectiveness of the Kampo medicine kamishoyosan for adjunctive treatment of tardive dyskinesia in patients with schizophrenia:a 16-week open trial. Psych Clin Neurosci. 2007;61(5):509–514.
38. Brar JS, Parepally H, Chalasani L, et al. The impact of olanzapine on tardive dyskinetic symptoms in a state hospital population. Ann Clin Psychiatry. 2008;20(3):139–144.
39. Kimiagar I, Dobronevsky E, Prokhorov T, et al. Rapid improvement of tardive dyskinesia with tetrabenazine, clonazepam and clozapine combined:a naturalistic long-term follow-up study. J Neurol. 2012;259(4):660–664.
40. Hatcher-Martin JM, Armstrong KA, Scorr LM, et al. Propranolol therapy for Tardive dyskinesia:a retrospective examination. Parkinsonism Related Dis. 2016;32:124–126.
41. Schooler NR, Kane JM. Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry. 1982;39:486–487.
42. XENAZINE summary of product characteristics [Internet]. Lundbeck UK LLP:St. Albans (UK); 2015. cited 2016 Dec02; Available from:https://www.lundbeck.com/upload/us/files/pdf/Products/Xenazine_SPC_GB_EN.pdf
43. XENAZINE prescribing information [Internet]. Deerfield (IL):Lundbeck; 2015; cited 2016 Dec02; Available from:http://www.lundbeck.com/upload/us/files/pdf/Products/Xenazine_PI_US_EN.pdf
44. Jankovic J, Clarence-Smith K. Tetrabenazine for the treatment of chorea and other hyperkinetic movement disorders. Exp Rev Neurother. 2011;11:1509–1523.
45. News release:FDA approves first drug to treat tardive dyskinesia [Internet]. Silver Spring (MD):Food and Drug Administration; 2017 Apr 11. cited 2017 May 10; Available from:https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm552418.htm
46. Bari M, Shiwach R, Jimenez R, et al. Open-label extension of KINECT:a phase 2 study of valbenazine (NBI-98854) for tardive dyskinesia [abstract]. Neurology. 2016;86(16Suppl.):S27.001.
47. Grigoriadis D, Comella C, Remington G, et al. Efficacy of valbenazine (NBI-98854) in subjects with tardive dyskinesia:results of a long-term extension study (KINECT 3 Extension) [poster M151]. Neuropsychopharmacology. 2016;41(Suppl. S1):S213.
48. Reches A, Burke RE, Kuhn CM, et al. Tetrabenazine, an amine-depleting drug, also blocks dopamine receptors in rat brain. J Pharmacol Exp Ther. 1983;225:515–521.
49. Ikarashi Y, Mizoquchi K. Neuropharmacological efficacy of the traditional Japanese Kampo medicine yokukansan and its active ingredients. Pharmacol Ther. 2016;166:84–95.
50. Okamoto H, Iyo M, Ueda K, et al. Yokukan-san:a review of the evidence for use of this Kampo herbal formula in dementia and psychiatric conditions. Neuropsychiatr Dis Treat. 2014;10:1727–1742.
51. Bernardo M, Vieta E, Ruiz JS, et al. Recommendations for switching antipsychotics. A position statement of the Spanish Society of Psychiatry and the Spanish Society of Biological Psychiatry. Rev Psiquiatr Salud Ment (Barcelona). 2011;4:150–168.
52. Asher SW, Aminoff MJ. Tetrabenazine and movement disorders. Neurology. 1981;31:1051–1054.
53. Ondo WG, Hannah PA, Jankovic J. Tetrabenazine treatment for tardive dyskinesia:assessment by randomized videotape protocol. Am J Psychiatry. 1999;156:1279–1281.
54. Jankovic J. Treatment of hyperkinetic movement disorders with tetrabenazine:a double-blind crossover study. Ann Neurol. 1982;11:41–47.
55. Guay DR. Tetrabenazine, a monoamine-depleting drug used in the treatment of hyperkinetic movement disorders. Am J Geriatr Pharmacother. 2010;8:331–373.
56. Jankovic J, Beach J. Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology. 1997;48:358–362.
57. American Psychiatric Association. Diagnostic criteria from DSM-IV-TR. Washington (DC):Arlington (VA):American Psychiatric Association; 2000.
58. Glazer WM, Morgenstern H, Doucette JT. Predicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medications. J Clin Psychiatry. 1993;54:133–139.
59. Casey DE, Gardos G. Tardive dyskinesia and neuroleptics:from dogma to reason. Washington (DC):American Psychiatric Association Press; 1986.
60. Glazer WM, Moore DC, Schooler NR, et al. Tardive dyskinesia:a discontinuation study. Arch Gen Psychiatry. 1984;41:623–627.
61. Glazer WM, Morgenstern H, Schooler N, et al. Predictors of improvement in tardive dyskinesia following discontinuation of neuroleptic medication. Br J Psychiatry. 1990;157:585–592.
62. Bhidayasiri R, Boonyawairoj S. Spectrum of tardive syndromes:clinical recognition and management. Postgrad Med J. 2011;87(1024):132–141.
63. Cloud LJ, Zutshi D, Factor SA. Tardive dyskinesia:therapeutic options for an increasingly common disorder. Neurotherapeutics. 2014;11(1):166–176.
64. Gerlach J, Reisby N, Randrup A. Dopaminergic hypersensitivity and cholinergic hypofunction in the pathophysiology of tardive dyskinesia. Psychopharmacologia. 1974;34:21–35.
65. Gardos G, Cole JO, Rapkin RM, et al. Anticholinergic challenge and neuroleptic withdrawal. Changes in dyskinesia and symptom measures. Arch Gen Psychiatry. 1984;41:1030–1035.
66. Casey DE, Denney D. Pharmacological characterization of tardive dyskinesia. Psychopharmacology. 1977;54:1–8.
67. Friis T, Christensen T, Gerlach J. Sodium valproate and biperiden in neuroleptic-induced akathisia, parkinsonism and hyperkinesia. A double-blind cross-over study with placebo. Acta Psychiatr Scand. 1983;67:178–187.
68. Reunanen M, Kaarnen P, Vaisanen E. The influence of anticholinergic treatment on tardive dyskinesia caused by neuroleptic drugs. Acta Neurol Scand. 1982;65(S90):278–279.
69. Yassa R. Antiparkinsonian medication withdrawal in the treatment of tardive dyskinesia:a report of three cases. Can J Psychiatry. 1985;30(6):440–442.
70. Desmarais JE, Beauclair L, Annable L, et al. Effects of discontinuing anticholinergic treatment on movement disorders, cognition and psychopathology in patients with schizophrenia. Ther Adv Psychopharmacol. 2014;4:257–267.